威麦宁胶囊联合化疗治疗肺癌的有效性和安全性的Meta分析OACSTPCD

OBJECTIVE:To evaluate the efficacy and safety of Weimaining capsules combined with chemotherapy in the treatment of lung cancer through Meta-analysis.METHODS:CNKI,Wanfang Data,VIP,CBM,PubMed,Embase,Springer,the Cochrane Library databases were retrieved to collect randomized controlled trial(RCT)of Weimaining capsules combined with chemotherapy in the treatment of lung cancer from the establishment of the database to Jan.17th,2024.The chemotherapy regimen was not limited.The observation group was treated with Weimaining capsules combined with chemotherapy,while the control group received conventional chemotherapy.After screening according to inclusion and exclusion criteria,Meta-analysis was performed by using RevMan 5.4 software.RESULTS:Totally 8 articles and 807 patients were finally enrolled,including 405 patients in observation and 402 patients in control group.Compared with chemotherapy alone,Weimaining capsules combined with chemotherapy could significantly increase the objective response rate(OR=2.63,95%CI=1.82-3.80,P<0.00001)and disease control rate(OR=2.71,95%CI=1.68-4.35,P<0.0001),improve immune function(CD4+/CD8+)(MD=0.54,95%CI=0.22-0.85,P=0.0007)and quality of life(OR=3.59,95%CI=1.60-8.06,P=0.002),and decrease the incidence of gastrointestinal reactions and bone myelosuppression(incidence of gastrointestinal reactions:OR=0.38,95%CI=0.21-0.69,P=0.001;incidence of myelosuppression:OR=0.30,95%CI=0.15-0.61,P=0.0008)of patients with lung cancer,the differences were statistically significant.CONCLUSIONS:In the treatment of lung cancer,Weimaining capsules combined with chemotherapy can significantly improve the objective response rate and disease control rate of patients,enhance the immune function,improve the quality of life,and reduce the incidence of adverse drug reactions(gastrointestinal reactions,myelosuppression suppression).However,the conclusions need to be confirmed by more and higher quality RCT.